Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study

Zeeshan Javed, Maria Papageorgiou, Harshal Deshmukh, Alan S. Rigby, Unaiza Qamar, Jehangir Abbas, Amer Y. Khan, Eric S. Kilpatrick, Stephen Atkin, Thozhukat Sathyapalan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type-2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular risk; therefore, empagliflozin may be of benefit for these women. The aim of this study was to compare the effects of empagliflozin vs metformin on anthropometric and body composition, hormonal and metabolic parameters in women with PCOS. Materials and methods: A randomized open-label study was conducted in women with PCOS who were randomized to either empagliflozin 25 mg (n = 19) or metformin 1500 mg (n = 20) daily for 12 weeks. The main outcomes assessed were changes in anthropometric and body composition, hormonal and metabolic parameters. Results: Univariate analysis showed significant differences in weight (empagliflozin: −1.4 ± 3.2% vs metformin: 1.2 ± 2.3%; P = 0.006), body mass index (empagliflozin: −1.4 ± 3.2% vs metformin: 1.1 ± 2.2%; P = 0.006), waist circumference (empagliflozin: −1.6 ± 2.8% vs metformin: 0.2 ± 2.1%; P = 0.029) and hip circumference (empagliflozin: −2.0 ± 3.0% vs metformin: 1.1 ± 1.9%; P = 0.001), basal metabolic rate (empagliflozin: −1.8 ± 2.9% vs metformin: 0.1 ± 1.9%, P = 0.024) and fat mass (empagliflozin: −0.7 ± 4.9% vs metformin, 3.2 ± 5.0%; P = 0.023) between the empagliflozin and the metformin groups. These differences were confirmed in linear regression analysis after adjustment for relevant covariates. There were no significant changes in hormonal or metabolic parameters between both groups. Conclusion: There was a significant improvement in anthropometric parameters and body composition, in overweight and obese women with PCOS after 12 weeks of treatment with empagliflozin compared to metformin, although no changes were seen in hormonal or metabolic parameters.

Original languageEnglish
JournalClinical Endocrinology
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Polycystic Ovary Syndrome
Metformin
Body Composition
empagliflozin
Sodium-Glucose Transport Proteins
Basal Metabolism
Waist Circumference
Type 2 Diabetes Mellitus
Hip
Weight Loss
Linear Models
Body Mass Index
Obesity
Fats
Regression Analysis

Keywords

  • body composition
  • empagliflozin
  • hormones
  • metabolic parameters
  • polycystic ovary syndrome
  • SGLT2 inhibitors

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Javed, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., ... Sathyapalan, T. (2019). Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. Clinical Endocrinology. https://doi.org/10.1111/cen.13968

Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome : A randomized controlled study. / Javed, Zeeshan; Papageorgiou, Maria; Deshmukh, Harshal; Rigby, Alan S.; Qamar, Unaiza; Abbas, Jehangir; Khan, Amer Y.; Kilpatrick, Eric S.; Atkin, Stephen; Sathyapalan, Thozhukat.

In: Clinical Endocrinology, 01.01.2019.

Research output: Contribution to journalArticle

Javed, Z, Papageorgiou, M, Deshmukh, H, Rigby, AS, Qamar, U, Abbas, J, Khan, AY, Kilpatrick, ES, Atkin, S & Sathyapalan, T 2019, 'Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study', Clinical Endocrinology. https://doi.org/10.1111/cen.13968
Javed, Zeeshan ; Papageorgiou, Maria ; Deshmukh, Harshal ; Rigby, Alan S. ; Qamar, Unaiza ; Abbas, Jehangir ; Khan, Amer Y. ; Kilpatrick, Eric S. ; Atkin, Stephen ; Sathyapalan, Thozhukat. / Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome : A randomized controlled study. In: Clinical Endocrinology. 2019.
@article{a46920d6da6746ba85583d4e59cae6a9,
title = "Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study",
abstract = "Background: Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type-2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular risk; therefore, empagliflozin may be of benefit for these women. The aim of this study was to compare the effects of empagliflozin vs metformin on anthropometric and body composition, hormonal and metabolic parameters in women with PCOS. Materials and methods: A randomized open-label study was conducted in women with PCOS who were randomized to either empagliflozin 25 mg (n = 19) or metformin 1500 mg (n = 20) daily for 12 weeks. The main outcomes assessed were changes in anthropometric and body composition, hormonal and metabolic parameters. Results: Univariate analysis showed significant differences in weight (empagliflozin: −1.4 ± 3.2{\%} vs metformin: 1.2 ± 2.3{\%}; P = 0.006), body mass index (empagliflozin: −1.4 ± 3.2{\%} vs metformin: 1.1 ± 2.2{\%}; P = 0.006), waist circumference (empagliflozin: −1.6 ± 2.8{\%} vs metformin: 0.2 ± 2.1{\%}; P = 0.029) and hip circumference (empagliflozin: −2.0 ± 3.0{\%} vs metformin: 1.1 ± 1.9{\%}; P = 0.001), basal metabolic rate (empagliflozin: −1.8 ± 2.9{\%} vs metformin: 0.1 ± 1.9{\%}, P = 0.024) and fat mass (empagliflozin: −0.7 ± 4.9{\%} vs metformin, 3.2 ± 5.0{\%}; P = 0.023) between the empagliflozin and the metformin groups. These differences were confirmed in linear regression analysis after adjustment for relevant covariates. There were no significant changes in hormonal or metabolic parameters between both groups. Conclusion: There was a significant improvement in anthropometric parameters and body composition, in overweight and obese women with PCOS after 12 weeks of treatment with empagliflozin compared to metformin, although no changes were seen in hormonal or metabolic parameters.",
keywords = "body composition, empagliflozin, hormones, metabolic parameters, polycystic ovary syndrome, SGLT2 inhibitors",
author = "Zeeshan Javed and Maria Papageorgiou and Harshal Deshmukh and Rigby, {Alan S.} and Unaiza Qamar and Jehangir Abbas and Khan, {Amer Y.} and Kilpatrick, {Eric S.} and Stephen Atkin and Thozhukat Sathyapalan",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/cen.13968",
language = "English",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome

T2 - A randomized controlled study

AU - Javed, Zeeshan

AU - Papageorgiou, Maria

AU - Deshmukh, Harshal

AU - Rigby, Alan S.

AU - Qamar, Unaiza

AU - Abbas, Jehangir

AU - Khan, Amer Y.

AU - Kilpatrick, Eric S.

AU - Atkin, Stephen

AU - Sathyapalan, Thozhukat

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type-2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular risk; therefore, empagliflozin may be of benefit for these women. The aim of this study was to compare the effects of empagliflozin vs metformin on anthropometric and body composition, hormonal and metabolic parameters in women with PCOS. Materials and methods: A randomized open-label study was conducted in women with PCOS who were randomized to either empagliflozin 25 mg (n = 19) or metformin 1500 mg (n = 20) daily for 12 weeks. The main outcomes assessed were changes in anthropometric and body composition, hormonal and metabolic parameters. Results: Univariate analysis showed significant differences in weight (empagliflozin: −1.4 ± 3.2% vs metformin: 1.2 ± 2.3%; P = 0.006), body mass index (empagliflozin: −1.4 ± 3.2% vs metformin: 1.1 ± 2.2%; P = 0.006), waist circumference (empagliflozin: −1.6 ± 2.8% vs metformin: 0.2 ± 2.1%; P = 0.029) and hip circumference (empagliflozin: −2.0 ± 3.0% vs metformin: 1.1 ± 1.9%; P = 0.001), basal metabolic rate (empagliflozin: −1.8 ± 2.9% vs metformin: 0.1 ± 1.9%, P = 0.024) and fat mass (empagliflozin: −0.7 ± 4.9% vs metformin, 3.2 ± 5.0%; P = 0.023) between the empagliflozin and the metformin groups. These differences were confirmed in linear regression analysis after adjustment for relevant covariates. There were no significant changes in hormonal or metabolic parameters between both groups. Conclusion: There was a significant improvement in anthropometric parameters and body composition, in overweight and obese women with PCOS after 12 weeks of treatment with empagliflozin compared to metformin, although no changes were seen in hormonal or metabolic parameters.

AB - Background: Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type-2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular risk; therefore, empagliflozin may be of benefit for these women. The aim of this study was to compare the effects of empagliflozin vs metformin on anthropometric and body composition, hormonal and metabolic parameters in women with PCOS. Materials and methods: A randomized open-label study was conducted in women with PCOS who were randomized to either empagliflozin 25 mg (n = 19) or metformin 1500 mg (n = 20) daily for 12 weeks. The main outcomes assessed were changes in anthropometric and body composition, hormonal and metabolic parameters. Results: Univariate analysis showed significant differences in weight (empagliflozin: −1.4 ± 3.2% vs metformin: 1.2 ± 2.3%; P = 0.006), body mass index (empagliflozin: −1.4 ± 3.2% vs metformin: 1.1 ± 2.2%; P = 0.006), waist circumference (empagliflozin: −1.6 ± 2.8% vs metformin: 0.2 ± 2.1%; P = 0.029) and hip circumference (empagliflozin: −2.0 ± 3.0% vs metformin: 1.1 ± 1.9%; P = 0.001), basal metabolic rate (empagliflozin: −1.8 ± 2.9% vs metformin: 0.1 ± 1.9%, P = 0.024) and fat mass (empagliflozin: −0.7 ± 4.9% vs metformin, 3.2 ± 5.0%; P = 0.023) between the empagliflozin and the metformin groups. These differences were confirmed in linear regression analysis after adjustment for relevant covariates. There were no significant changes in hormonal or metabolic parameters between both groups. Conclusion: There was a significant improvement in anthropometric parameters and body composition, in overweight and obese women with PCOS after 12 weeks of treatment with empagliflozin compared to metformin, although no changes were seen in hormonal or metabolic parameters.

KW - body composition

KW - empagliflozin

KW - hormones

KW - metabolic parameters

KW - polycystic ovary syndrome

KW - SGLT2 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85063756862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063756862&partnerID=8YFLogxK

U2 - 10.1111/cen.13968

DO - 10.1111/cen.13968

M3 - Article

AN - SCOPUS:85063756862

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

ER -